Patients with inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis, often have comorbid anxiety and depression that affects their quality of life (QoL) and management of
Currently approved monoamine modulating antidepressant and anxiolytic pharmaceutics fail in over one third of patients due to delayed and variable therapeutic effect, adverse reactions preceding the t